Abivax Shares On the Move Again As Filing Catches Trader Interest Ahead of June
Abivax SA’s Nasdaq-listed shares rose 3.5% to $124.03 Thursday as investors awaited late-Q2 topline data from its Phase 3 trial of obefazimod for ulcerative colitis. A May 20 SEC filing showed shareholders approved capital-raising mandates and a U.S. ATM program with 78.2% support. The company recently repurchased royalty certificates for $90 million, partly in ADSs. Paris shares closed at 105.10 euros, up 2.14%.
